Navigation Links
Imaging agents predict breast cancer response to endocrine therapy
Date:7/2/2012

Reston, Va. (July 2, 2012) Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage. Estrogen receptor-α (ERα) status is an important factor in determining the most appropriate treatment for breast cancer patients, especially for those who are ERα+ and likely to respond well to hormone-based, or endocrine, therapies.

Prominent professor and research chemist Michael J. Welch, PhD, who passed away in May, was a contributing author for this research. "Throughout his career, Dr. Welch specialized in the synthesis of new radiolabeled compounds for medical imaging, with a special emphasis on the growing numbers of applications in PET," said Dominique Delbeke, MD, PhD, editor of The Journal of Nuclear Medicine. Noted for his ability to see beyond the immediate aspects of basic work to potential future applications, Welch was both a prime mover and an integral part in the development of PET as it transitioned from a compelling investigative idea to widespread clinical acceptance. "Many of his discoveries and research will live on well into the future," said Delbeke.

The study, "Small-Animal PET of Steroid Hormone Receptors Predicts Tumor Response to Endocrine Therapy Using a Preclinical Model of Breast Cancer" was an example of his unique approach to research.

"Positron emission tomography, or PET, has typically been used to identify the target for endocrine therapy in breast cancer by demonstrating that ER is present in tumors using F-18-fluoroestradiol (FES)-PET, or by monitoring for hormone-induced changes in tumor metabolism'metabolic flare' with F-18-fluorodeoxyglucose (FDG)-PET once therapy has begun. What is novel about our study is that we chose to image progesterone receptor levels to see how the estrogen signaling pathway is functioning in response to endocrine therapy," said Amy Fowler, MD, PhD, lead author of the study.

In the study, mice with mammary cell lines (SSM1, SSM2 and SSM3) derived from STAT1-deficient mammary tumorswhich are ERα+/PR+ and similar to the majority of human breast cancerswere imaged. Small-animal PET/computed tomography (CT) was performed using F-18-FES to image estrogen receptor status, F-18-fluoro furanyl norprogesterone (F-18-FFNP) for progesterone receptor status, and FDG for glucose uptake.

Initial imaging of the cell lines showed that SSM3 tumors displayed the greatest F-18-FES and F-18-FFNP uptake, and therefore, the SSM3 cell line was used to test the response to estradiol, an ER agonist, and fulvestrant, a pure ER antagonist. Upon treatment with estradiol, it was determined that PR expression is estrogen-inducible and indicative of ERα signaling in the SSM3 tumors. Mice treated with fulvestrant showed early decreases in F-18-FFNP uptake after initiation of therapy, prior to measurable growth inhibition. SSM2 tumors, which were not growth-inhibited by fulvestrant despite also being ERα+/PR+, showed no change in F-18-FFNP uptake after initiation of therapy. These data support the potential use of PR imaging with F-18-FFNP PET of patients with ERα+ breast cancer at baseline and shortly after initiation of endocrine therapy to distinguish between responders and nonresponders, and thus help facilitate the selection of therapies most appropriate for individual patients.

"An important goal of molecular imaging in cancer research is to noninvasively predict early responses to therapies in order to guide further management," noted Fowler. "Our work using a preclinical model of breast cancer helps support the notion that molecular imaging can achieve this goal by testing whether the target utilized for a specific therapy is not only present but also functional."

An estimated one in eight women will develop breast cancer in her lifetime. According to the American Cancer Society, an estimated 280,000 new cases of breast cancer were diagnosed among women in 2011, and nearly 40,000 died from the disease.


'/>"/>

Contact: Susan Martonik
smartonik@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Mount Sinai is first in New York state to perform new Alzheimers imaging test in clinical setting
2. Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
3. Fox Chase researchers find no disparities in imaging before breast cancer surgery
4. Study examines necessity of additional imaging in PET/CT oncologic reports
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
7. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
8. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
9. Pig stomach mucins are effective as anti-viral agents for consumer products
10. Greater L.A. Heating Up, Climate Experts Predict
11. Blood test for pregnant women could predict risk of having dangerously small babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... ... 28, 2017 , ... The Radiology Business Management Association (RBMA) is ... its new executive director. Mr. Still was selected through a careful months-long search by ... he is known to our members, has been a part of building the RBMA ...
(Date:3/28/2017)... ... 28, 2017 , ... Qualidigm , the mission-driven national ... a new, more expansive office space in order to accommodate its growing number ... office building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
(Date:3/27/2017)... March 27, 2017 Therapix ... pharmaceutical company specializing in the development of cannabinoid-based drugs, ... in the United States ... representing 40 ordinary shares of the Company, at ... Therapix has granted the underwriters a 45-day over-allotment ...
Breaking Medicine Technology: